【Polaris Pharmaceuticals-KY】Suspension of Phase III Clinical Trial for ADI-PEG 20 in Leiomyosarcoma (LMS)
Polaris Pharmaceuticals announced on May 25, 2026, that it is suspending its Phase III clinical trial of ADI-PEG 20 combined with Gemcitabine and Docetaxel for Leiomyosarcoma (LMS) following a recommendation from the DSMB.
📋 Article Processing Timeline
- 📰 Published: May 25, 2026 at 09:00
- 🔍 Collected: May 26, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: June 1, 2026 at 23:39 (159h 38m after Collected)
1. Product: ADI-PEG 20. 2. Background: The Phase III multi-center trial for LMS was reviewed by the Data Safety Monitoring Board (DSMB). Based on their recommendation, the company will suspend the trial and optimize the patient population and trial design. 3. Impact: No material impact on financial or operational status. 4. Future: The company will follow DSMB recommendations and regulatory requirements for the suspension and subsequent procedures.
FAQ
Why was the clinical trial suspended?
Based on the recommendation of the Data Safety Monitoring Board (DSMB).